<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10576661</article-id><article-id pub-id-type="pmc">2362939</article-id><article-id pub-id-type="pii">6690803</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690803</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Scinto</surname><given-names>A F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ferraresi</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Milella</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tucci</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Santomaggio</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Pasquali-Lasagni</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Vecchio</surname><given-names>M R Del</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Campioni</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Nardi</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cognetti</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Medical Oncology I, <label>2</label>Division of Surgical Oncology III, <label>3</label>Department of Radiotherapy, Regina Elena Cancer Institute, Viale Regina Elena 291, Rome 00161, Italy</aff><aff id="aff4"><label>4</label>Department of Radiotherapy, Hospital S Maria dell Scala, Piazza Duomo 2, Siena 53100, Italy</aff><aff id="aff5"><label>5</label>Pneumology Unit, USL 10/D, Viale Pieraccini 24, Florence 50139, Italy</aff><pub-date pub-type="ppub"><month>11</month><year>1999</year></pub-date><volume>81</volume><issue>6</issue><fpage>1031</fpage><lpage>1036</lpage><history><date date-type="received"><day>06</day><month>01</month><year>1999</year></date><date date-type="rev-recd"><day>27</day><month>05</month><year>1999</year></date><date date-type="accepted"><day>07</day><month>06</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>From March 1993 to February 1997, 43 eligible patients with inoperable stage IIIA (ten patients) and stage IIIB (33 patients), histologically confirmed NSCLC received 3 courses of the ICE combination (ifosfamide 1.5 g m<sup>&#x02212;2</sup> and mesna 750 mg m<sup>&#x02212;2</sup> two times a day, cisplatin 25 mg m<sup>&#x02212;2</sup> and etoposide 100 mg m<sup>&#x02212;2</sup>, all administered intravenously (i.v.) on days 1&#x02013;3 every 3 weeks) with G-CSF support. After three cycles, patients were submitted to radical surgery or received two additional courses of the ICE regimen and/or curative radiotherapy. Grade 3&#x02013;4 neutropenia occurred in 21&#x00025; of 114 evaluable courses, but was of short duration, leading to neutropenic fever in 5&#x00025; of the courses. Severe thrombocytopenia and anaemia were observed in 13&#x00025; and 3&#x00025; of the courses respectively. Non-haematological toxicity was generally mild with only two episodes of reversible renal impairment. The overall response rate after three chemotherapy courses was 69&#x00025; (28 partial responses, one complete response). Ten patients (8/10 patients in stage IIIA, 2/33 patients in stage IIIB) underwent radical surgery. Median TTP for patients not undergoing surgery (<italic>n</italic> = 33) was 8 months (range 3&#x02013;34+); median DFS for patients rendered NED by surgery (<italic>n</italic> = 10) was 26 months (range 1&#x02013;54+). Median OS for the entire group was 12.5 months (range 2&#x02013;57+). The ICE regimen is active in locally advanced NSCLC with acceptable toxicity and warrants further exploration as induction chemotherapy in larger series. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>non-small-cell lung cancer</kwd><kwd>locally advanced</kwd><kwd>inoperable</kwd><kwd>chemotherapy</kwd><kwd>ICE</kwd><kwd>G-CSF</kwd></kwd-group></article-meta></front></article>


